ABSTRACT
The Brazilian western Amazon region is currently experiencing its largest laboratory confirmed Oropouche virus (OROV) outbreak, with nearly 6,000 reported cases in the states of Amazonas (AM), Acre (AC), Rondônia (RO), and Roraima (RR), between August 2022 and March 2024. Here, we sequenced and analyzed 382 full-length OROV genomes from human samples collected between 2022 and 2024 from all four states, aiming to trace the origin and genetic evolution of OROV leading to the current outbreak. Genomic analyses revealed that the recent upsurge of OROV cases in the Brazilian Amazon region coincides with the emergence of a novel reassortant viral lineage containing the M segment of viruses detected in the eastern Amazon region from 2009 to 2018 and the L and S segments of viruses detected in Peru, Colombia, and Ecuador from 2008 to 2021. The novel reassortant OROV lineage likely emerged in the Central region of the AM state between 2010 and 2014 and displayed a long-range silent dispersion during the second half of the 2010s. The 2022-2024 OROV epidemic was spatially segregated into three major subpopulations located in RR, AMACRO (a bordering region between AC, RO, and AM-Southern region), and AM-Central (which includes the Amazonas’ capital, Manaus) regions. The peak of OROV transmissions in all regions occurred during the rainy season in the Amazon basin. Furthermore, our phylodynamics reconstructions showed that OROV spread was driven mainly by short-range (< 2 km) movements, with an average dispersal rate ≤ 1.2 km/day, consistent with the pattern of an active flight of infected vectors. Nevertheless, a substantial proportion (22%) of long-range (> 10 km) OROV migrations were also detected, consistent with viral dispersion via human activities. Our data provides an unprecedented view of the real-time spread and evolution of a neglected emergent human pathogen. Moreover, our results emphasize the need for widespread, long-term genomic surveillance to better understand the real burden of OROV within and beyond the Amazon region.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding support FAPEAM Call 04/2022/FIOCRUZ/FAPEAM/FAPERO INOVACAO NA AMAZONIA; Amazonia +10; FAPEAM Call 023/2022 INICIATIVA AMAZONIA +10; Inova Fiocruz Inova Amazonia; Rede Genomica de Vigilancia em Saude do Estado do Amazonas REGESAM (Resolucao n 002/2008, 007/2018 e 005/2019 PRO-ESTADO/FAPEAM); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq Institutos Nacionais de Ciencia e Tecnologia (INCT VER) e Chamada CNPq/MCTI 10/2023 - Faixa B Grupos Consolidados Universal 2023 (421620/2023-4). GLW and GB are supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) through their productivity research fellowships (307209/2023-7 and 304883/2020-4). ED and AR are supported by Fundacao de Amparo a Pesquisa e Inovacao do Espirito Santo (FAPES).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Amazonas State University (CAAE: 72678923.8.0000.5016), which waived signed informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
